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Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous and 
aggressive tumor originating from the epithelial lining of the upper aero-digestive tract 
accounting for 300,000 annual deaths worldwide due to failure of current therapies. The 
natural killer group 2D (NKG2D) receptors on natural killer (NK) cells and several T cell 
subsets play an important role for immunosurveillance of HNSCC and are thus targeted 
by tumor immune evasion strategies in particular by shedding of various NKG2D ligands 
(NKG2DLs). Based on plasma and tumor samples of 44 HNSCC patients, we found that 
despite compositional heterogeneity the total plasma level of NKG2DLs correlates with 
NK cell inhibition and disease progression. Strikingly, based on tumor spheroids and 
primary tumors of HNSCC patients, we found that NK cells failed to infiltrate HNSCC 
tumors in the presence of high levels of NKG2DLs, demonstrating a novel mechanism 
of NKG2DL-dependent tumor immune escape. Therefore, the diagnostic acquisition of 
the plasma level of all NKG2DLs might be instrumental for prognosis and to decipher 
a patient cohort, which could benefit from restoration of NKG2D-dependent tumor 
immunosurveillance. Along these lines, we could show that removal of shed NKG2DLs 
(sNKG2DLs) from HNSCC patients’ plasma restored NK  cell function in  vitro and in 
individual patients following surgical removal of the primary tumor. In order to translate 
these findings into a therapeutic setting, we performed a proof-of-concept study to test 
the efficacy of adsorption apheresis of sNKG2DLs from plasma after infusion of human 
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MICA in rhesus monkeys. Complete removal of MICA was achieved after three plasma 
volume exchanges. Therefore, we propose adsorption apheresis of sNKG2DLs as a 
future preconditioning strategy to improve the efficacy of autologous and adoptively 
transferred immune cells in cellular cancer immunotherapy.
Keywords: adsorption apheresis, head and neck squamous cell carcinoma, immunotherapy of cancer, natural 
killer cells, natural killer group 2D ligands, tumor immune escape
inTrODUcTiOn
Head and neck squamous cell carcinoma (HNSCC) is a highly 
aggressive solid tumor originating from the epithelial lining of 
the upper aero-digestive tract and is characterized by phenotypic, 
etiological, biological, and clinical heterogeneity (1, 2). With 
approximately 650,000 newly diagnosed patients and 300,000 
deaths annually, HNSCC is the sixth most common cancer 
worldwide (3, 4). The relative frequency of HNSCC correlates 
with tobacco and alcohol consumption (5) and human papil-
lomavirus (HPV) infection (6–8). Current therapeutic regimens 
combine surgery, radiotherapy and chemotherapy with 5-year 
survival rates of 30–65 and 5–58% for the tumor stages T1–T4 
and N0–N3, respectively (9, 10). However, conventional therapies 
are associated with high morbidity and toxicity and have mainly 
palliative benefits for patients with metastatic disease or incurable 
recurrence (11, 12).
Human natural killer (NK) cells are innate lymphoid effector 
cells which can be divided into two subsets according to their cell 
surface expression levels of CD56 and CD16. CD56dim/CD16bright 
NK  cells predominantly mediate natural cytotoxicity, whereas 
the CD56bright/CD16dim subset plays a role in immune regulation 
through a high cytokine secretion potential (13, 14). NK  cells 
mediate immunosurveillance of malignantly transformed cells 
(15, 16). Their cytotoxicity is regulated by a dynamic balance 
of agonistic and antagonistic signaling from activating and 
inhibitory receptors (16). Among the major activating recep-
tors is the natural killer group 2D (NKG2D) receptor (17–19), 
which is also expressed on T cell subtypes and NKT cells (20). 
NKG2D recognizes the structurally related ligands (NKG2DLs) 
MHC class I chain-related protein A (MICA), MICB, and several 
UL-16-binding proteins commonly overexpressed on tumor cells 
(21–23). However, shedding of NKG2DLs leads to impaired cyto-
toxicity of NK cells and T cells due to loss of antigenic NKG2DLs 
and shed NKG2DL (sNKG2DL)-induced downregulation of 
NKG2D (24–26). Consequently, patients suffering from various 
cancers (27–33) demonstrated an inverse correlation of sMICA 
plasma levels and NKG2D-dependent NK cell cytotoxicity. Since 
all sNKG2DLs engage with a common receptor, the cumulative 
level of all sNKG2DLs is decisive for their biological/clinical 
effect. However, the majority of studies so far investigated only 
individual sNKG2DLs.
Cellular immunotherapy based on autologous or adoptive 
NK or T  cells, including adoptive chimeric antigen receptor 
(CAR)-functionalized cells, represents a novel therapeutic 
concept for cancer treatment (34, 35). All of these cells might be 
affected by sNKG2DLs in the same way than the patients’ endog-
enous NKG2D+ immune cells thus limiting therapeutic efficacy. 
Therefore, the current study aimed at molecular characterization 
of NKG2D-dependent immune escape and development of a 
procedure to restore NKG2D-dependent immunosurveillance in 
HNSCC patients.
MaTerials anD MeThODs
Patients
Plasma from 44 HNSCC patients (mean age: 65  years) and 
12 age-matched healthy volunteers (mean age: 55  years) was 
analyzed. Patients’ demographics and tumor characteristics are 
summarized in Table 1. Tumor staging was assigned according 
to the TNM classification of the International Union Against 
Cancer. Thirty of the HNSCC patients were studied at primary 
diagnosis and 14 patients with recurrent/metastatic (relapse) 
disease. From the patients with primary diagnosis, blood samples 
of 26 patients were taken before therapeutic treatment (treatment 
naïve), while 4 patients had surgery and/or radiotherapy before 
sample collection. Ten patients with recurrent disease were under 
palliative therapy during sample collection, while four patients 
were currently not under therapy.
animal experiments
Two male rhesus macaques (age 6 years) from the German Primate 
Center breeding colony (German Primate Center, Göttingen) 
were used for the in vivo experiments (pilot study and apheresis). 
All experimental procedures were done under inhalation anes-
thesia. The animals were i.v. injected with sMICA*04 at 100 µg/l 
blood volume (blood volume corresponds to approximately 7% 
of body weight). Plasma volume was calculated based on indi-
vidual hematocrit. For the apheresis, animals were connected to 
a Life18™ apheresis unit equipped with an adsorber cartridge 
(anti-MICA antibody covalently coupled to sepharose Cl-4B at 
0.95 mg AMO1/g sepharose) via a double lumen catheter in the 
vena femoralis. Apheresis was started 15 min post-injection with 
a flow-rate of 25–30 ml/min until three complete plasma volume 
exchanges were reached. During apheresis, animals got heparin 
as anticoagulant (50 U/kg). Blood and urine samples were taken 
every 15 min.
cell culture
Primary NK  cells were purified (>95% pure) from buffy coats 
of healthy volunteers kindly provided by the German Red 
Cross Blood Service (Institute for Transfusion Medicine and 
Immunohematology, Medical School, Goethe University 
Frankfurt, Germany) with written donor approval and approval 
by the Ethics Committee of the Goethe University Frankfurt 
(Frankfurt am Main, Germany, permit #329/10). Therefore, 
peripheral blood mononuclear cells (PBMCs) were isolated by 
a density gradient with Biocoll (Biozol, Germany) followed by 
TaBle 1 | clinical parameters and frequencies of head and neck 
squamous cell carcinoma patients.
Parameter absolute numbers and frequency (%)
age (mean: 65 years)
20–40 1 (2.3)
40–60 15 (34.1)
60–80 24 (54.5)
>80 4 (9.1)
sex
Male 39 (88.6)
Female 5 (11.4)
Disease stage
I 3 (6.8)
II 4 (9.1)
III 7 (15.9)
IVA 19 (43.2)
IVB 2 (4.5)
IVC 6 (13.6)
Other 3 (6.8)
localization of tumor
Oral cavity 10 (22.7)
Oropharynx 9 (20.5)
Hypopharynx 12 (27.3)
Larynx 7 (15.9)
Larynx/hypopharynx 3 (6.8)
Other 3 (6.8)
Therapy
No therapy 30 (68.2)
Post surgery 2 (4.5)
Post surgery and RCTx 2 (4.5)
Palliative RTx/CTx 10 (22.7)
status
Primary 30 (68.2)
Recurrent (relapse) 14 (31.8)
TnM classification
T
1 5 (11.4)
2 8 (18.2)
3 9 (20.5)
3–4/4 17 (38.6)
n.d. 5 (11.4)
N
0 16 (36.4)
1 6 (13.6)
2 1 (2.3)
2b 9 (20.5)
2c 7 (15.9)
3 3 (6.8)
n.d. 2 (4.5)
M
0 38 (86.4)
1 6 (13.6)
human papillomavirus status
Positive 4 (9.1)
Negative 34 (77.3)
n.d. 6 (13.6)
noxa
None 11 (25.0)
Smoking 16 (36.4)
Alcohol 1 (2.3)
Smoking + alcohol 16 (36.4)
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untouched NK cell isolation using magnetic cell separation with 
the human NK  cell isolation kit (Miltenyi Biotec, Germany). 
NK  cells were expanded and activated for 7  days in X-Vivo10 
medium (Lonza, Switzerland) supplemented with 5% human 
serum (Life Technologies, USA), 1,000 IU/ml IL-2 (Promokine, 
Germany), and NK  cell activation/expansion kit (Miltenyi 
Biotec, Germany). The cell lines FaDu (HTB-43, human pharynx 
squamous cell carcinoma cells), CAL27 (CRL-2095, human 
tongue squamous cell carcinoma cells), and Detroit562 (CCL-
138, human pharyngeal carcinoma cells) were purchased from 
the American Type Culture Collection. HNSCC cell lines were 
cultured in MEM medium (Life Technologies, USA). SiHa (grade 
II, human cervix squamous cell carcinoma) cells kindly provided 
by Dr. Adelheid Cerwenka (DKFZ, Heidelberg, Germany) were 
cultured in DMEM medium (Life Technologies, USA). All media 
were supplemented with 10% FCS (PAA and PAN Biotech, 
Germany), 1% penicillin/streptomycin (Life Technologies, USA), 
2 mM l-glutamine (Life Technologies, USA), and 1 mM sodium 
pyruvate for HNSCC cell lines (Life Technologies, USA).
cytokine Measurement with cytometric 
Bead array (cBa)
The concentrations of IFNγ, TNFα, IL-1, IL-6, IL-8, IL-10, 
MCP-1, RANTES, MIP-1α, MIP-1β, and TGF-β1 in plasma of 
HNSCC patients and healthy donors were determined using the 
BD™ CBA Flex Set System (BD Bioscience, USA), according to 
manufacturer’s instructions. Samples were diluted 1:30 for TGF-
β1 or 1:4 for all other sets and tested in duplicates. Samples were 
measured with the BD FACS Array™ and analyzed with FCAP 
Array Software (BD Bioscience, USA). Cytokine levels of HNSCC 
patient samples were normalized to healthy controls, and data are 
represented as x-times median control.
elisa
For analyses of sNKG2DL levels in the plasma of HNSCC 
patients, healthy donors, rhesus monkeys, or tumor spheroid 
supernatants [concentrated 10-fold using Amicon centrifugal 
filter units (Merckmillipore, Germany)], samples were diluted 1:2 
and measured in duplicates. Soluble NKG2DLs were analyzed as 
described (27, 36–38). Briefly, ELISA plates (Greiner Bio-One, 
Austria) were coated with mouse anti-human MICA (clone 
AMO1), anti-human MICA/B (clone BAMO1), anti-human 
ULBP1 (clone AUMO5), anti-human ULBP2 (clone BUMO1), 
or goat anti-human ULBP3 antibodies (AF1517; R&D Systems, 
USA). After saturation with BSA blocking solution (Candor, 
Germany), the plates were incubated with soluble MICA*04 or 
recombinant Fc-fusion proteins of human MICB, ULBP1/2/3 
(1599-MB-050, 1380-UL-050, 1298-UL-050, 1517-UL-050; R&D 
Systems, USA) as standards. For detection and quantification of 
soluble ligands, mouse anti-human MICA/B (clone BAMO3), 
anti-human MICB (clone BMO2), anti-human ULBP1 (clone 
AUMO2), or anti-human ULBP2 (MAB1298; R&D Systems, 
USA) antibodies were used in combination with a goat anti-
mouse IgG2a horseradish peroxidase (HRP)-conjugated antibody 
(1080-05; Southern Biotechnologies, USA). For sULBP3, the 
mouse anti-human ULBP3 antibody (clone CUMO3) was used 
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in combination with a goat anti-mouse IgG1 HRP-conjugated 
antibody (1070-05; Southern Biotechnologies, USA). Following 
visualization with 3,3′,5,5′-tetramethylbenzidine substrate (KPL, 
Germany), signals were measured in a microtiter plate reader 
(λ =  450 nm) and analyzed with Prism 6 software (GraphPad, 
USA). Data of tumor spheroids were calculated as mean ± SEM 
per 10,000 cells (per spheroid) of three independent experiments 
(n = 3). Data of plasma samples were calculated as mean ± SEM. 
Statistical analysis was performed using one-way analysis of vari-
ance (ANOVA).
Depletion of snKg2D ligands Using 
antibody-Functionalized Beads
Soluble NKG2DLs were depleted from plasma of HNSCC patients, 
healthy donors, or CAL27 cell culture supernatants (collected on 
d3 of culture and 10× concentrated). Samples were incubated 
with a cocktail of Protein A Dynabeads (Life Technologies, 
USA) coupled to anti-human MICA (clone AMO1), anti-human 
MICB (MAB1599), anti-human ULBP1 (MAB1380), anti-human 
ULBP2 (MAB1298), or anti-human ULBP3 (MAB1517; all R&D 
Systems, USA) antibodies.
For the depletion of sMICA, the anti-MICA antibody (clone 
AMO1) was covalently coupled to MACSxpress beads (Miltenyi 
Biotec, Germany). Human plasma of healthy donors supple-
mented with 20  ng/ml sMICA*04 or culture supernatants of 
C1R cells transfected with MICA*01/04/07 and MICA*08 (38) 
were incubated with antibody-coupled beads overnight. Beads 
and bound sNKG2DLs were removed from the supernatants by 
magnetic bead separation on a MACSxpress separator (Miltenyi 
Biotec, Germany) following centrifugation.
cytotoxicity assays
Primary human NK cells of different healthy donors were pre-
incubated overnight with sNKG2DL-depleted or non-depleted 
plasma of HNSCC patients or healthy donors’ plasma as 
controls. SiHa target cells were labeled with carboxyfluorescein 
succinimidyl ester (CFSE; Life Technologies, USA) according 
to manufacturer’s instructions. Labeled SiHa target cells and 
pre-treated NK cells were cocultured at an E:T ratio of 15:1 for 
2 h. NK cells were labeled with mouse anti-human CD45-APC 
antibodies (clone 5B1, Miltenyi Biotec, Germany), and live/dead 
cell discrimination was achieved by staining with SytoxBlue 
(Life Technologies, USA) prior to the measurement on a BD 
FACSCanto II instrument equipped with a 96-well plate high 
throughput sampler (HTS). Cellular event counts were analyzed 
with FlowJo software. The percentage of cell lysis was calculated 
by evaluation of viable (CFSE+/SytoxBlue−) and dead (CFSE+/
SytoxBlue+) target cells. Data were normalized to mean of healthy 
control and are represented as mean ± SEM of triplicates of a rep-
resentative experiment. Statistical significance was determined 
by one-way ANOVA.
Tumor spheroid assays
Cytotoxicity assays were performed as previously described 
(39). In brief, CFSE-labeled HNSCC and SiHa solid tumor 
spheroids were co-incubated with primary human NK cells at 
appropriate E:T ratios (5:1) in medium without IL-2 for 48 h. 
For inhibition, NK  cells were pre-incubated overnight with 
non-/sNKG2DL-depleted CAL27 SN. For endpoint analyses, 
single tumor spheroids were dissociated, NK cells were labeled 
with a mouse anti-human CD45-APC antibody (clone 5B1; 
Miltenyi Biotec, Germany), and live/dead cell discrimination 
was achieved by staining with SytoxBlue (Life Technologies, 
USA). Complete samples were measured on a FACS Canto II 
instrument equipped with a HTS and cellular event counts 
were analyzed with FlowJo software. The percentage of cell lysis 
was calculated by evaluation of viable (CFSE+/SytoxBlue−) and 
dead (CFSE+/SytoxBlue+) target cells. Data are represented as 
mean  ±  SEM of eight spheroids. Statistical significance was 
determined by one-way ANOVA.
For infiltration studies, tumor cells and CAL27 SN or sMICA*01 
pre-treated NK cells were seeded 1:1 into agarose coated 96-well 
plates. Individual spheroids (n > 8) were collected after 48 h and 
embedded into OCT compound (Sakura). Cryosections (7 µm) 
of solid tumor spheroids were stained with rabbit anti-human 
cleaved caspase-3 (clone 5A1E; Cell Signaling Technology, USA) 
and mouse anti-human CD45 (clone 2B11 +  PD7/26; DAKO, 
Germany) and analyzed by standard two-step polymer methods 
with Envision kits (DAKO, Germany). 3,3′-diaminobenzidine 
(DAB) and permanent red or 3-amino-9-ethylcarbazol (AEC) 
were used as chromogen. Counterstaining was performed using 
hematoxylin (DAKO, Germany) according to the manufacturer’s 
instructions. Phase-contrast pictures of solid spheroids were ana-
lyzed by triple measurement of independent spheroids (n = 8) for 
each condition by ImageJ software (40). Tumor spheroid volume 
was calculated based on area analysis of solid spheroids assuming 
a perfect sphere. The number of infiltrated NK cells was calcu-
lated as percentage of CD45+ NK cells from whole cell numbers 
in spheroid cryosections. Data are represented as mean ± SEM 
of eight tumor spheroid cryosections and statistical analysis was 
performed using unpaired Student’s two-tailed t-test.
Flow cytometry
Cryo-preserved PBMCs of healthy volunteers or HNSCC patients 
and corresponding disintegrated primary tumor samples were 
stained with a cocktail of mouse anti-human CD3-APC.Cy7 
(clone HIT3a), anti-human CD4-PacificBlue (clone OKT4), anti-
human CD8a-AlexaFluor700 (clone HIT8a), anti-human CD16-
FITC (clone 3G8), anti-human CD56-PE.Cy7 (clone HCD56) 
(all, BioLegend, USA), anti-human CD45-Pe.Flour610 (clone 
HI30; eBioscience, USA), and anti-human CD314-PE (clone 
BAT221; Miltenyi Biotec, Germany). For cell viability, Aqua Dead 
Cells stain (Thermo Fisher Scientific, USA) was used. Cellular 
events were measured on a Gallios cytometer and analyzed using 
Kaluza software (both Beckmann Coulter, USA). Percentage of 
NK cell subsets and mean fluorescent intensity ratios for NKG2D 
expression were calculated from CD45+ lymphocyte fraction.
histology
Paraffin sections of primary HNSCC tumors were stained with 
anti-human CD3 (clone SP7; Thermo Scientific, USA), anti-
human CD8 (clone C8/144B; Dako), anti-human CD20 (clone 
L26; Dako), anti-human CD68 (clone PG-M1; Dako), anti-human 
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CD56 (clone 123C3; Invitrogen), and anti-human CD163 (clone 
MRQ-26; Cell Marque) antibodies using the BOND-MAX auto-
mated IHC-stainer (Leica Biosystems) according to the manu-
facturer’s instructions in the Institute of Pathology (University of 
Cologne, Germany). Numbers of infiltrating cells in the invasive 
margin and tumor core of HNSCC sections were analyzed sepa-
rately. Cell counts per high power field (HPF) at 400× magnifica-
tion were assessed by an experienced pathologist in five HPF of 
invasive margin and tumor core of every slide, respectively, and 
the mean positive cell count per HPF was calculated.
statistical analysis
Statistical analyses were performed using Prism 6 software 
(GraphPad, USA). Data are presented as mean  ±  SEM as 
indicated. Statistical significance was evaluated using one-way 
ANOVA with repeated measurements and post  hoc test after 
Bonferroni or unpaired Student’s two-tailed t-test as indicated. 
Differences were considered statistically significant at p < 0.05.
resUlTs
elevated snKg2Dl Plasma levels 
correlate with Disease stage in hnscc
Previously, we could show a correlation of high sMICA plasma 
levels and impaired NK cell cytotoxicity in patients with HNSCC 
(33, 41). Since these studies only investigated sMICA in NKG2D-
dependent tumor immune escape, in the current study, we deter-
mined the levels of all the shed NKG2DLs (sMICA, sMICB, and 
sULBP1–3) in plasma samples of 44 HNSCC patients (patients’ 
characteristics are summarized in Table 1).
Significantly elevated levels of individual sNKG2DLs were 
detected in patients’ plasma when compared to those observed 
in the plasma of 12 age-matched healthy donors (Figure  1A). 
Moreover, the burden of sNKG2DLs in patients with advanced 
disease vs. healthy donors was significantly increased, whereas no 
significant difference between primary and relapsed HNSCC was 
observed (Figure 1B). Comparison of treatment naïve patients 
with patients currently under palliative chemo- or radiotherapy 
or after tumor resection showed a therapy induced reduction 
of sNKG2DL levels (Figure S1A in Supplementary Material). 
Notably, sNKG2D ligands were found to peak in the plasma of 
patients with advanced disease (Figure 1C), suggesting that the 
total level of sNKG2DLs represents an important clinical param-
eter (Figure S1B in Supplementary Material).
immunosuppressive and Proinflammatory 
cytokines in hnscc Patients
To further assess the immune status of HNSCC patients, we ana-
lyzed the plasma levels of indicative cytokines and chemokines. 
Elevated plasma levels could be detected for the immunosuppres-
sive and proinflammatory factors TGF-β1, MIP-1β, RANTES, 
IL-8, MCP-1, and IL-6. However, compared to the plasma levels 
of healthy controls, HNSCC patients showed no significant dif-
ferences in the levels of IFN-γ, TNF-α, IL-10, IL-1β, and MIP-1α 
(Figures 2A,B). Moreover, aberrant cytokine or chemokine levels 
were not correlated to disease stage (Figure  2A) or primary 
vs. relapsed HNSCC, except for TGF-β1 showing an increase 
between stage I and IV (2677 vs. 5358 pg/ml) (Figure 2C).
inhibition of nK cell cytotoxicity by 
snKg2Dls in Patients’ Plasma
To investigate the inhibitory potency of sNKG2DLs on NK cell 
cytotoxicity, we performed cytotoxicity assays with primary 
human NK cells after pre-incubation with plasma from HNSCC 
patients, healthy controls, or anti-NKG2D blocking antibodies. 
As target cells, a human cervix carcinoma cell line (SiHa) was 
used whose killing is strongly dependent on NKG2D. Two-thirds 
of HNSCC plasma samples significantly diminished target cell 
killing compared to plasma of healthy donors (Figure  3A). To 
verify the sNKG2DL-dependency, we depleted sMICA/B and 
sULBP1-3 from patients’ plasma with antibody-coupled beads. 
The ligands were removed with efficacies between 61.9 and 93.2% 
(Figure 3B). Depletion of sNKG2DLs efficiently restored NK cell 
cytotoxicity (Figure 3C; Figure S2A in Supplementary Material), 
whereas depletion of healthy plasma had no effect. Thus, NK cell 
inhibition is mostly due to blocking and downregulation of the 
NKG2D receptor on NK cells (Figures S2B,C in Supplementary 
Material). Since we found high levels of TGF-β1, which is known 
to inhibit NKG2D (42, 43), we correlated the cytotoxic capacity of 
pre-incubated NK cells with the plasma levels of sNKG2DLs and 
TGF-β1. High levels of both, sNKG2DLs (>2.5 ng/ml; median: 
7.6  ng/ml) and TGF-β1 (>3,000  pg/ml; median: 5,319  pg/ml) 
showed an additive effect on NK cell inhibition when compared 
to plasma with low sNKG2DLs (<2.5  ng/ml; median: 1.4  ng/
ml) and TGF-β1 (<3,000  pg/ml; median: 2,045  pg/ml) levels 
(Figure 3D). This is in accordance with our previous results dem-
onstrating an additive effect of sMICA and TGF-β1 on NKG2D-
dependent inhibition of NK cell cytotoxicity in HNSCC (33, 41). 
Nevertheless, the sole depletion of sNKG2DLs was sufficient to 
restore NK cell cytotoxicity, assuming shedding of ligands as a 
key mechanism of NKG2D-dependent tumor immune escape in 
HNSCC. Moreover, plasma samples of one representative patient 
showed significantly reduced levels of sNKG2DLs and TGF-β1 
after surgery (Figure 3E), which were correlated with increased 
NK cell cytotoxicity (Figure 3F). These findings demonstrate a 
direct link between tumor burden, NKG2DL shedding and TGF-
β1 release and was supported by a patient with recurrent disease 
(Figures S2D,E in Supplementary Material).
snKg2Dls Diminish nK cell cytotoxicity 
and infiltration of Tumor spheroids
Next, we analyzed NKG2D-dependent tumor immune escape in 
tumor spheroids, which resemble many features of poorly vascu-
larized and avascular regions of solid tumors or micrometastases 
and allow for systematic studies of molecular parameters in a highly 
controlled microenvironment (39, 44, 45). Tumor spheroids were 
grown from HNSCC (FaDu, CAL27, and Detroit562) and SiHa 
(39) cell lines, which show characteristic NKG2DL expression 
patterns and are highly susceptible to NKG2D-dependent killing 
(Figures S3 and S4A,B in Supplementary Material).
To investigate the impact of sNKG2DLs on NK cell cytotoxic-
ity, tumor spheroids were cocultured for 48 h at an E:T ratio of 
FigUre 1 | Disease stage-dependent increase of shed nKg2Dl (snKg2Dl) levels. (a) Levels of sNKG2DLs in plasma of head and neck squamous cell 
carcinoma (HNSCC) patients (n = 44) compared to age-matched healthy donors (n = 12) quantified by ELISA. (B) Cumulative sNKG2DL levels (sum of sMICA/B 
and sULBP1–3) grouped according to disease stage (left: early = stage I + II; advanced = III + IV) or primary vs. relapsed HNSCC (right). (c) Plasma levels of 
individual sNKG2DLs grouped according to disease stage (early = stage I + II; advanced = III + IV). Data are presented as mean ± SEM of representative 
experiments. Statistical significance was assessed by unpaired, two-tailed Student’s t-test (a) and one-way analysis of variance (B,c). ns, non-significant.
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5:1 with NK  cells pre-incubated with a cocktail of sNKG2DLs 
(CAL27 SN: 27.63  ng/ml sNKG2DLs) or sNKG2DLs-depleted 
CAL27 supernatant (sNKG2DLs: 2.66  ng/ml) (Figures  4A,B). 
NK  cells in basal culture medium served as controls. NK  cells 
efficiently destroyed tumor spheroids (Figure 4A; Figure S4C in 
Supplementary Material). By contrast, in the presence of high 
levels of sNKG2DLs, NKG2D-dependent killing was reduced 
by 25% for FaDu, 19% for CAL27, and 46% for SiHa tumor 
spheroids (Figure  4A). Importantly, impaired tumor spheroid 
destruction and NKG2D-downregulation could be completely 
restored by specific depletion of sNKG2DLs (Figure 4A; Figure 
S4D in Supplementary Material).
FigUre 2 | continued
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Since antitumor activity of NK cells correlates with infiltration 
capacity into tumors (46, 47), we investigated NK  cell infiltra-
tion into tumor spheroids in the absence and presence of high 
levels of sNKG2DLs. Untreated NK cells (kill CO) or NK cells 
pre-treated with CAL27 SN or purified sMICA (20 ng/ml) were 
mixed with HNSCC cells at a 1:1 ratio. Tumor spheroids were 
monitored by light microscopy for 48 h. In the absence of sNK-
G2DLs, NK cell killing was accompanied by massive infiltration 
FigUre 2 | elevated immunosuppressive factors in head and neck squamous cell carcinoma (hnscc) patients. Patients’ plasma was analyzed for the 
levels of the cytokines TGF-β1, IL-6, IL-8, IL-10, IL-1β, IFN-γ, TNF-α and the chemokines MIP-1α, MIP-1β, RANTES, and MCP-1 by cytometric bead array. (a) 
Heat-map representation of shed NKG2DL levels (see Figure 1), cytokine and chemokine levels as x-times median control (CO; n = 12 healthy donors) grouped 
according to disease stage (I–IVC). Color code: yellow = normal; orange = elevated; and red = highly elevated. (B) Quantification of chemokine and cytokine levels 
compared to healthy controls. Data are presented as mean ± SEM. (c) TGF-β1 plasma levels grouped according to primary vs. relapsed (left) or disease stage 
(right: early = stage I + II; advanced = III + IV). Statistical significance was assessed by unpaired, two-tailed Student’s t-test (B) and one-way analysis of variance 
(c). ns, non-significant.
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into tumor spheroids indicated by staining of tumor spheroid 
cryosections with CD45-specific antibodies (Figure 4C; Figures 
S5A,B in Supplementary Material). Roughly 66, 38, and 65% of 
the cells comprising the FaDu, CAL27, or SiHa tumor spheroids, 
respectively, were NK cells (Figure 4D). In contrast, under inhibi-
tory conditions (in the presence of sMICA or CAL27 SN), NK cell 
cytotoxicity, shown as tumor spheroid volume reduction (Figure 
S5C in Supplementary Material), was inhibited. This inhibition 
was accompanied by drastically reduced NK cell infiltration with 
only 26, 26, or 19% of the cells of FaDu, CAL27, or SiHa tumor 
spheroids being NK cells, respectively (CAL27 SN; Figure 4D). 
Interestingly, the same amount of sMICA alone was sufficient for 
NK cell inhibition, with 38, 21, and 29% of NK cell infiltration 
for FaDu, CAL27, and SiHa tumor spheroids, respectively, when 
compared to the cocktail of shed ligands in the CAL27 SN, sug-
gesting that the total burden of NKG2DLs might be crucial for 
NK cell dysfunction in cancer patients. Additionally, infiltrated 
pre-treated NK  cells were often double positive for CD45 and 
cleaved caspase-3 compared to untreated NK  cells. Therefore, 
we speculate that under inhibitory conditions NK  cells might 
proliferate less and become apoptotic. Moreover, both NK  cell 
subtypes (CD56bright/CD16+/−; CD56dim/CD16+) could infiltrate 
into tumor spheroids (Figure S5D in Supplementary Material).
low nK cell infiltration of Primary hnscc
To further investigate tumor infiltration in  vivo, primary 
HNSCC tumor sections were stained for CD3+ and CD8+ 
T cells, CD20+ B cells and CD56+ NK cells, as well as CD68+/
CD163+ macrophages (Figures  5A,B). Infiltrating cells were 
analyzed separately for the invasive margin (IM) or tumor core 
(TC). T and B cells were predominantly found in the IM (CD3 
T  cells: mean 71 cells/HPF; CD8 T  cells: mean 50 cells/HPF; 
CD20 B cells: 200 cells/HPF). In contrast, only a small propor-
tion of lymphocytes could infiltrate into the tumor core (CD3 
T  cells: mean 17 cells/HPF; CD8 T  cells: mean 20 cells/HPF; 
CD20 B cells: 4 cells/HPF). No differences could be observed 
for CD8+ T  cells when compared to the whole CD3+ T  cell 
population. Moreover, tumor-associated macrophages were 
equally distributed throughout the tissue. Interestingly, only 
very low numbers or a complete absence of NK cells could be 
found in the tumor tissues (IM/TC: mean 2 cells/HPF). The low 
infiltration potential of the different lymphocyte populations 
is indicative for the insufficient tumor rejection in HNSCC 
patients. For further analysis, NK  cells of HNSCC patients’ 
PBMCs and corresponding dissociated tumor samples were 
subjected to flow cytometry experiments. The total number of 
circulating NK  cells in the CD45+ lymphocyte population of 
PBMCs was nearly unchanged compared to healthy controls 
(Figure  5C). Regarding regulatory (CD56bright/CD16+/−) and 
cytotoxic (CD56dim/CD16+) NK cells, HNSCC patients showed 
a slight shift toward the CD56bright NK  cell subpopulation. 
Analysis of tumor samples confirmed the histological staining 
showing that only a minor proportion of tumor-associated 
lymphocytes were NK  cells. Interestingly, the infiltrated 
NK cells were predominantly from the regulatory subpopula-
tion, whereas cytotoxic NK cells were nearly absent. Moreover, 
analysis of NKG2D expression levels showed a small increase 
compared to healthy controls of maximum twofold for the 
CD56bright population (Figure 5D).
Preclinical evaluation of adsorption 
apheresis of snKg2Dls in rhesus 
Macaques
Our data suggest that the cumulative sNKG2DL level is indica-
tive for the extent of NKG2D-dependent tumor immune escape. 
Consequently, sNKG2DL plasma depletion by adsorption apher-
esis might be a clinical intervention strategy to significantly boost 
antitumor efficacy of autologous and, if combined with cell-based 
therapies, adoptively transferred or allogeneic immune cells. For 
proof-of-concept studies, we employed a human sMICA-specific 
antibody, raised by immunizing BALB/c mice with a mixture 
of MICA*01 and MICA*04 (38), with an epitope in the α1-
helical domain (Figures S6A,B in Supplementary Material). To 
FigUre 3 | continued
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test its depletion efficacy, human plasma of 20 healthy donors 
supplemented with recombinant sMICA*04 (production and 
purification of sMICA*04, see Figures S6C–E in Supplementary 
Material) or cell culture SN containing allelic sMICA variants were 
incubated with antibody-coupled magnetic beads. The antibody 
showed a depletion efficacy of 89–97% of sMICA allelic variants 
frequently found in the Caucasian population (48) independent 
of the donor immune status (Figures  6A,B). Moreover, beside 
FigUre 3 | continued  
shed nKg2Dls (snKg2Dls)-dependent inhibition and restoration of natural killer (nK) cell cytotoxicity. (a) Cytotoxicity assay of NK cells with 
CFSE-labeled SiHa target cells (E:T ratio 15:1; 2 h). NK cells were pre-incubated with head and neck squamous cell carcinoma plasma, healthy plasma (CO), or 
natural killer group 2D (NKG2D) blocking antibodies (B). Cell lysis was calculated by analysis of dead (CFSE+/SytoxBlue+) and viable (CFSE+/SytoxBlue−) target cells. 
Data were normalized to mean of healthy controls and are represented as mean ± SEM of triplicates of a representative experiment. (B) The sum of sNKG2DL 
plasma levels pre-/post-depletion presented as mean ± SEM of duplicates. (c) Cytotoxicity assays with NK cells pre-incubated with non-(PS) or NKG2D ligand 
(NKG2DL)-depleted patients’ plasma (PS depleted) according to (a). (D) Lysis of target cells grouped according to sNKG2DLs (+low = 0–2.5 ng/ml and +++ high 
>2.5 ng/ml) and TGF-β1 (+low = 0–3,000 pg/ml and +++ high >3,000 pg/ml) plasma levels. (e) Plasma levels of sNKG2DLs and TGF-β1 of one patient pre-/
post-surgery presented as mean ± SEM of duplicates. (F) Cytotoxicity assay of NK cells pre-treated with plasma pre-/post-surgery according to (a). Statistical 
significance was assessed by two-way analysis of variance (ANOVA) (a–c,e) or one-way ANOVA (D,F), ns, non-significant, *p = 0.01–0.05, **p = 0.001–0.01, 
***p < 0.001, and ****p < 0.0001.
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sNKG2DLs also exosomes containing NKG2DLs (MICA*08, 
Figure 6B) (49) could be efficiently removed.
For preclinical validation of adsorption apheresis, we 
used a rhesus macaque (Macaca mulatta) model. Human and 
rhesus MICA display a sequence identity of 79%, human and 
rhesus NKG2D a sequence identity of 94% (Figures S6F,G in 
Supplementary Material). In a pilot study, two rhesus monkeys 
were injected with 100 µg sMICA*04 per liter blood volume, and 
sMICA plasma levels were analyzed over 3  h. About 15–25% 
of the initially injected sMICA could be found in the plasma 
15 min after injection. An exponential decrease of sMICA could 
be observed during the first 150 min reaching a stable plasma 
level with diffusion equilibrium of about 3–5  ng/ml after 3  h, 
which resembles the plasma levels found in cancer patients 
(Figure S7A in Supplementary Material). Notably, no renal 
clearance, proteolytic degradation of sMICA (Figures S7B,C in 
Supplementary Material), or immune reaction against sMICA 
was observed (Figure S7D in Supplementary Material). These 
data indicate that the decreasing sMICA plasma levels reflect 
equilibrium formation of sMICA’s body distribution.
For adsorption apheresis, two animals were injected with 
sMICA*04, and the apheresis was started 15 min post-injection 
until three exchanges of the animals’ plasma volume were 
reached. Analysis of sMICA plasma levels showed a nearly com-
plete depletion of sMICA from the plasma after only three plasma 
volume exchanges with 1.44 ± 0.06 and 3.48 ± 1.79% remaining 
sMICA*04 when compared to the endpoints reached by body 
distribution without treatment (24.17 ± 0.09 and 27.98 ± 0.46% 
remaining sMICA*04 in the two animals, respectively) 
(Figures  6C,D). Notably, since the two monkeys were healthy 
without signs of immune challenge at the time of the experiment, 
the basal level of NKG2D on the monkeys’ T and NK cells was 
not affected by human sMICA (Figures S7E–G in Supplementary 
Material). In conclusion, we suggest that adsorption apheresis of 
sNKG2DLs from patients’ plasma might be a promising combina-
torial medical approach to overcome NKG2D-dependent tumor 
immune escape and to improve the efficacy of (cellular) cancer 
immunotherapy.
DiscUssiOn
Natural killer group 2D-dependent tumor immune escape mech-
anisms contribute to impaired tumor surveillance. Previously, 
we could show a correlation of increased sMICA and TGF-β1 
plasma levels with diminished NK cell cytotoxicity in untreated 
HNSCC patients (33, 41). NKG2D-dependent immune escape 
based on the release of sNKG2DLs has been described in a variety 
of cancers (50, 51), but most studies mainly concentrated on 
sMICA and sMICB. Therefore, the knowledge of the cumulative 
sNKG2DL levels in cancer patients and their impact is still scarce. 
In the present study, profiling of HNSCC plasma revealed that the 
cumulative level of the sNKG2DLs (sMICA/B and sULBP1-3) is 
patient specific, correlates with disease progression and tumor 
load, and is indicative for NKG2D-dependent tumor immune 
escape in HNSCC. This is in accordance with studies showing that 
high sMICA and sMICB plasma levels are associated with tumor 
progression and poor prognosis in advanced oral squamous cell 
carcinoma (32, 52) and other malignancies such as prostate cancer 
and multiple myeloma (31, 53). The accumulation of sNKG2DLs 
in advanced diseases might be associated with the upregulation of 
matrix metalloproteinases, which mediate proteolytic cleavage of 
NKG2DLs, with increased tumor invasiveness (54). Moreover, our 
data suggest a prominent role for sULBP1 and sULBP3 in HNSCC 
when compared to sMICA/B. The diverse NKG2DL expression 
patterns in different cancer entities and in individual patients 
might be explained by differential transcriptional regulation, 
which can be influenced by many factors of the tumor microen-
vironment and cancer therapies (55–57). Interestingly, palliative 
chemo- and radiotherapy had little effect on sNKG2DL levels. 
In addition, altered cytokine and chemokine levels in HNSCC 
patients were highly heterogeneous with only TGF-β1 being 
disease stage dependent, but commonly showed an immunosup-
pressive, proinflammatory, and proangiogenic phenotype (58, 
59). Moreover, high numbers of tumor-associated macrophages, 
predominantly of the M2 phenotype, found in primary HNSCC 
tumor tissues further corroborated the immunosuppressive state 
of HNSCC. In contrast to previous reports (33, 58, 60, 61), we 
could not detect significant alterations in the levels of TNF-α, 
IL-10, or IFN-γ. It should be noted that analysis of plasma from a 
relatively small patient cohort with different tumor localization, 
stages, additional carcinogens (e.g., HPV-infection, smoking) 
and treatments might contribute to the divergent results. Lathers 
and Young (58) showed in a study analyzing HNSCC plasma of 
101 patients a bias toward Th2 cytokines (e.g., IL-4, IL-6, and 
IL-10), but a loss of interrelationship between Th1/Th2 cytokines 
toward advanced disease when compared to healthy controls. The 
shift toward Th2 cytokines is in accordance with other studies 
(61, 62) and our results of patients’ plasma and primary tumor 
sections. Moreover, Green et  al. (62) could show that HNSCC 
treatment reduced Th2 cytokines in the plasma of 101 HNSCC 
FigUre 4 | natural killer (nK) cell cytotoxicity and infiltration toward tumor spheroids is inhibited by shed nKg2Dls (snKg2Dls). (a) NK cells 
incubated with non-/sNKG2DL-depleted CAL27 supernatant (SN) or medium (kill CO) prior to co-incubation with FaDu, CAL27, or SiHa tumor spheroids (E:T ratio 
5:1, 48 h). Tumor spheroid lysis was calculated by analysis of live (CFSE+/SytoxBlue−) and dead (CFSE+/SytoxBlue+) tumor cells. Bars correspond to mean ± SEM 
of eight tumor spheroids. (B) sNKG2DL levels of non-/depleted CAL27 SN analyzed by ELISA. Data are shown as mean ± SEM of duplicates. (c) NK cells treated 
with CAL27 SN, sMICA01, or untreated (kill CO) prior to coculturing with FaDu cells for 48 h. Representative phase-contrast pictures at 50× magnification are 
shown (size bar = 100 µm). Cryosections of spheroids were stained for NK cells (anti-CD45 antibody, red) and apoptosis (anti-active caspase-3 antibody, brown). 
Representative pictures are shown at 200× magnification (size bar = 200 µm). (D) Percentage of infiltrated NK cells in FaDu, CAL27, or SiHa tumor spheroids. Bars 
correspond to mean ± SEM of 10 vision fields. Statistical significance was assessed by one-way analysis of variance (a) and unpaired, two-tailed Student’s t-test 
(D). ns, non-significant.
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FigUre 6 | sMica depletion by adsorption apheresis using an anti-Mica antibody. (a) Depletion of sMICA*04 (20 ng/ml) from human plasma (n = 20 
donors) with antibody-coupled beads. sMICA*04 plasma levels post-depletion measured by ELISA and normalized to initial sMICA*04 level. Data represented as 
mean ± SEM of duplicates of a representative experiment. (B) Depletion of sMICA alleles (sMICA*01, sMICA*04, sMICA*07, and sMICA*08) from C1R supernatants. 
Beads with mouse IgG1 antibody served as control (CO). sMICA levels measured by ELISA and normalized to initial sMICA. Data represented as mean ± SEM of 
duplicates of a representative experiment. (c,D) Animals were injected with 100 µg/l blood volume sMICA*04. Apheresis was started 15 min post-injection using a 
Life18™ apheresis unit (Miltenyi Biotec) equipped with an adsorber cartridge (anti-MICA antibody covalently coupled to sepharose). sMICA plasma concentrations 
were determined by ELISA every 15 min and normalized to initial sMICA (15 min post-injection). Data are represented as mean ± SEM of duplicates. Body 
distribution (pilot study): open square, black; apheresis: open circles, red. Arrows indicate the time point of one plasma volume (PV) exchange [(c) PV = 525 ml; 
(D) PV = 365 ml]. Statistical significance was assessed by unpaired, two-tailed Student’s t-test.
FigUre 5 | continued  
low infiltration of lymphocytes in primary head and neck squamous cell carcinoma (hnscc). (a) Paraffin sections of primary HNSCC tumors stained for 
CD3+/CD8+, CD20+ or CD56+ lymphocytes, or CD68+/CD163+ macrophages. Consecutive sections of a representative patient are shown (magnification 200×).  
(B) Number of infiltrating lymphocytes and macrophages quantified by counting infiltrating cells in High power fields of the tumor slides. Total cell numbers/HPF are 
plotted as mean ± SEM (n = 11 patients). (c) Flow cytometric analysis of natural killer (NK) cell subpopulations (CD56bright/CD16+/− and CD56dim/CD16+) of patients’ 
peripheral blood mononuclear cells (PBMCs) and corresponding tumor tissues. PBMCs from healthy donors served as control. NK cell numbers were calculated 
and plotted as % of CD45+ lymphocytes (n = 9 patients; n = 4 healthy controls). (D) Corresponding natural killer group 2D (NKG2D) expression levels of NK cell 
subpopulations plotted as mean fluorescent intensity (MFI) over background (n = 9 patients). Statistical significance was assessed by one-way analysis of variance. 
ns, non-significant.
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patients, while not increasing Th1 cytokines confirming a rebal-
ance of Th1/Th2 cytokines in HNSCC. However, the results 
of the different studies on cytokine levels in HNSCC varied 
markedly for individual factors underlining the heterogeneous 
nature of this cancer. The results on cytokine levels could vary 
using different assays and depends on the material analyzed, since 
the complex cytokine and chemokine network is modulated by 
different cell types such as tumor cells, stromal cells, and immune 
cells and depends on the cellular cross-talk of these cells (59). In 
this respect, Pries and colleagues (63) could show that HNSCC 
tumor cell lines alone could secrete high levels of IL-6/IL-8 but no 
significant levels of IL-4 and IL-10 in the absence of infiltrating 
immune cells. Moreover, Bose et  al. (61) showed cytokines 
analyzed from mononuclear cell culture supernatants isolated 
from HSNCC patients rather than from HNSCC plasma samples. 
Therefore, comparison of different studies might be difficult and a 
uniform diagnostic method for clinical use should be established 
to further evaluate the immune status in a large patient cohort.
Previous studies showed a NKG2D-dependent NK and T cell 
inhibition through sMICA/B molecules in different cancer 
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entities (24, 28, 33, 50, 64). In our study, HNSCC patients’ plasma 
led to reduced NK  cell cytotoxicity by blocking the NKG2D 
receptor. We could see an additional inhibitory effect when 
HNSCC plasma contained high levels of both, sNKG2DLs and 
TGF-β1 [current study and in Ref. (33)]. This is in accordance with 
studies showing that suppression of NKG2D-mediated antitumor 
functions can be correlated with high TGF-β1 plasma levels in 
neuroblastoma and colorectal cancer patients (42, 43). Moreover, 
tumor resection in one patient led to reduced sNKG2DL and 
TGF-β1 plasma levels and increased NK cell cytotoxicity. These 
results are supported by a study of Crane et al. showing restored 
NKG2D-dependent cytotoxicity of NK and T cells after tumor 
resection in glioma patients (65). Importantly, we could show 
that specific depletion of sNKG2DLs could completely restore 
NKG2D-dependent killing of monolayer cell cultures and 3D 
tumor spheroids, demonstrating that NK cell dysfunction is pre-
dominantly governed by shed NKG2DLs. Interestingly in case of 
patient 37, high sNKG2DLs and a median TGF-β1 level showed 
only moderate NK cell inhibition (prior to ligand depletion) and 
depletion of sNKG2DLs from plasma had only a minor effect on 
restoration of NK cell cytotoxicity. A marginal increase in NK cell 
cytotoxicity after sNKG2DL depletion, which was not significant, 
could also be observed in three more samples. It is interesting 
that in these cases NK cells showed relatively high cytotoxicity 
toward tumor cells before sNKG2DL depletion compared with 
NK cells incubated with healthy plasma. In this respect, it was 
shown that NKG2D expression can be increased by different 
cytokines including IL-2, IL-12, IL-15, and type I interferons 
(66). Moreover, it cannot be excluded that these plasma samples 
contain factors which act on other inhibitory and/or activating 
NK cell receptors and, therefore, partially counteract the effect 
of sNKG2DLs and/or TGF-β1. However, our further analyses of 
cytokine and chemokine plasma levels could not give any addi-
tional hints on these factors. Regarding the complexity of human 
plasma and the complexity of the NK cell receptor system, which 
regulates NK cell cytotoxicity, the identification of all components 
regulating NK cell functions is hard to address and needs further 
investigations. On the other hand, the composition and nature of 
sNKG2DL levels might play a role for the extend of NK cell inhibi-
tion. In this respect, it could be shown that NKG2DLs released on 
exosomes triggered significantly more NKG2D-donwregulation 
than monovalent sNKG2DLs (49, 67, 68). In accordance with 
that, Clayton et  al. could show that NKG2DLs and TGF-β1 
released from mesothelioma cell-generated exosomes markedly 
decreased NKG2D surface expression on activated NK and T cells 
(69). Notably, the inhibitory impact of TGF-β1 on NK cells in vivo 
might be stronger by acting through the suppressive function of 
Tregs (70), which are increased in HNSCC patients as shown by 
Bose et al. (61). Therefore, profiling of sNKG2DLs and TGF-β1 as 
diagnostic/prognostic markers might be relevant for individual-
ized therapy to decipher the time point and patient cohort to 
benefit from an intervention strategy for NKG2D-dependent 
tumor immune escape.
Using tumor spheroids (39), we could show for the first 
time a correlation between NKG2D-dependent NK  cell 
inhibition and decreased infiltration. Interestingly, the same 
amount of shed MICA, purified from supernatant of tumor 
cells, inhibited NK cell cytotoxicity and infiltration to the same 
extent as a cocktail of sNKG2DLs. This supports the hypothesis 
that the composition of sNKG2DLs and especially the level of 
high-affinity ligands in the plasma might be important for the 
extend of NK cell inhibition. However, the detailed mechanism 
of sNKG2DL-dependent suppression of NK  cell infiltration 
needs further investigation. One possible mechanism could be 
NK  cell exhaustion through NKG2D-downregulation resulting 
in low NK cell functions and viability as reported by Rossi et al. 
showing a correlation of NKG2D and NKp46 downregulation 
and decreased NK cell viability and function after histone dea-
cetylase inhibitor treatment (71). The reduced infiltration into 
tumor spheroids also reflects the situation in primary tumors 
of HNSCC patients. Whereas low numbers of CD3+/CD8+ and 
CD20+ tumor-infiltrating lymphocytes could be found, nearly 
no infiltration of CD56+ NK cells (and presumably NKT cells) 
could be detected. This is in accordance with a study showing low 
NK cell infiltration in primary tumor tissues and regional lymph 
nodes in oral cancer patients (72). Moreover, HNSCC patients 
had decreased numbers of peripheral cytotoxic CD56dim/CD16+ 
NK  cells and a shift toward CD56bright NK  cells. A bias toward 
CD56bright NK cell subpopulation and reduced CD16 expression 
was also described for patients with advanced cancers, such as 
melanoma, breast cancer, esophageal squamous cell carcinoma, 
and pediatric leukemia (73–76). The reduction in CD16+ NK cell 
subsets is further correlated to decreased NK cell cytotoxicity and 
the immunosuppressive milieu of advanced cancers (73, 74, 77). 
Tumor infiltration of NK cells is associated with a better progno-
sis in several cancer entities, such as colorectal cancer, non-small 
cell lung cancer, and clear cell renal cell carcinoma (78–82). For 
HNSCC, several studies showed a positive correlation of high 
NK  cell infiltration, especially in HPV+ HNSCC, in primary 
tumors, and overall survival rates (83–85). Thus, low numbers 
of infiltrated NK cells might be one explanation for insufficient 
HNSCC immunosurveillance, and these patients might benefit 
from sNKG2DL depletion.
In our in vitro cytotoxicity assays, we could show that deple-
tion of sNKG2DLs efficiently restored NK  cell functions. In a 
proof-of-concept study with rhesus monkeys, we have shown 
that quantitative removal of sMICA can be achieved by adsorp-
tion apheresis. Therefore, we suggest adsorption apheresis of 
sNKG2DLs as a supportive therapy for HNSCC patients in order 
to restore cytotoxicity of autologous NKG2D+ immune cells, 
such as NK cells, NKT cells, and T cells. Moreover, adsorption 
apheresis prior to administration of cellular therapies might help 
to maintain and prolong the cytotoxic activity of adoptively trans-
ferred and allogeneic immune cells after haploidentical stem cell 
transplantation, which can be affected by sNKG2DLs (28), and 
favor the success of immune cell therapies. Besides healthy donor 
derived cell products this will also include CAR-functionalized 
T cells and NK cells.
Currently, several lines of argumentation indicate that adsorp-
tion apheresis of sNKG2DLs might be a powerful supportive 
intervention in cancer therapy. First, one individual patient post 
surgery had significantly lower sNKG2DL plasma levels than 
before surgery (Figure  3E). This demonstrates that the overall 
sNKG2DL level correlates with tumor burden and that tumor 
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load determines the maximum level of the equilibrium of plasma 
sNKG2DLs. Second, after apheresis, the fraction of NKG2D+ 
immune cells that are capable of attacking NKG2DL+ tumor 
cells will be drastically increased. In turn, the tumor mass and its 
capacity to reproduce sNKG2DLs will be reduced. Third, since 
adsorption apheresis represents a minimal invasive procedure 
similar to hemodialysis of diabetic patients, we assume that 
it can be repeated several times after cellular therapy in order 
to scavenge reappearing sNKG2DLs from patients’ plasma. 
Previous results indicate that sMICA plasma levels in pediatric 
neuroblastoma patients’ plasma remained low for more than 
72 h after adoptive transfer of NK cells from healthy donors most 
likely due to scavenging of sMICA on NKG2D in the plasma 
membrane of the transferred NK cells (28). Therefore, we expect 
that periodic “refreshing” of the NKG2D+ immune cells will lead 
to constant shrinking of the tumor mass, sustained reduction 
of sNKG2DL plasma levels, and extended antitumor activity of 
NKG2D+ immune cells.
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